What are the best treatments for Adenoid Cystic Carcinoma?

The primary treatment for Adenoid Cystic Carcinoma (ACC) is surgical resection, often followed by adjuvant radiation therapy to manage the high risk of local recurrence and perineural invasion. While systemic therapies for advanced Adenoid Cystic Carcinoma are evolving, treatment must be highly personalized based on the tumor's site, stage, and molecular profile.

What are the primary treatments for Adenoid Cystic Carcinoma?

Because Adenoid Cystic Carcinoma is known for its slow growth but high propensity for perineural invasion, the goal of initial treatment is complete surgical excision with clear margins. When surgery is not feasible or margins are close, adjuvant radiation therapy—specifically intensity-modulated radiation therapy (IMRT) or proton beam therapy—is standard. For patients with recurrent or metastatic Adenoid Cystic Carcinoma, systemic therapies are considered, though they are generally palliative rather than curative.

What medications are used for Adenoid Cystic Carcinoma?

There is currently no FDA-approved systemic therapy specifically labeled for Adenoid Cystic Carcinoma. However, clinicians may utilize targeted therapies or chemotherapy off-label for advanced disease. Common approaches include:

• Tyrosine Kinase Inhibitors (TKIs): Drugs like Lenvatinib or Axitinib (Inlyta) may be used to inhibit tumor angiogenesis.


• Chemotherapy: Agents such as cisplatin or doxorubicin are sometimes employed, though response rates are historically modest.


• Clinical Trial Agents: Many patients participate in trials investigating Notch pathway inhibitors or other molecular-targeted agents.

Which specialists should be on my care team?

Due to the complexity of Adenoid Cystic Carcinoma, a multidisciplinary tumor board is essential. Your care team should ideally include:

• Head and Neck Surgical Oncologist


• Radiation Oncologist


• Medical Oncologist


• Pathologist (specializing in salivary gland tumors)


• Speech and Language Pathologist (for post-surgical rehabilitation)

How does treatment effectiveness vary between patients?

Treatment success for Adenoid Cystic Carcinoma varies significantly based on the primary site (e.g., salivary glands vs. lacrimal glands), the presence of solid versus tubular/cribriform histology, and the extent of perineural invasion. With 119 members in the DiseaseMaps.org community, we recognize that patient experiences differ, and regular surveillance is critical, as recurrences can occur many years after initial diagnosis.

Next steps

• Consult with a high-volume academic center specializing in head and neck oncology.


• Ask your oncologist about genetic tumor profiling to identify potential clinical trial eligibility.


• Connect with the 119 members of the DiseaseMaps.org Adenoid Cystic Carcinoma community for shared experiences.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult your personal oncology team regarding your specific clinical situation.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Adenoid Cystic Carcinoma.


• National Comprehensive Cancer Network (NCCN) Guidelines: Head and Neck Cancers.


• Adenoid Cystic Carcinoma Research Foundation (ACCRF).


• PubMed: Current management strategies for salivary gland malignancies.